NCT00192361已完成3 期
A Randomized, Double-Blind Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- The primary endpoint of the study was the determination of the proportion of placebo recipients from whom any of the vaccine strains were isolated.
研究概览
简要总结
To assess whether CAIV-T was transmitted from vaccinated children to their unvaccinated contacts in a day care setting; and if so, to estimate the rate of transmission.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double
入排标准
- 年龄范围
- 8 Months 至 36 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •who were at least 8 months and less than 36 months of age (had not reached their 3rd birthday) at the time of enrollment, and in good health as determined by medical history, physical examination, and clinical judgment;
- •whose parent or legal guardian had provided written informed consent after the nature of the study had been explained;
- •who, along with their parent or legal guardian, were available for the duration of the study (42 days post-vaccination of first study dose or 42 days post-vaccination of supplemental dose of CAIV-T);
- •whose parent/legal guardian could be reached by telephone by study staff for the postimmunization contacts;
- •who attended day care at least three days per week and four hours per day;
- •who was one of at least 4 children in a contact group/playroom (at least 4 children in such a group were required to be randomized in the study).
排除标准
- •whose parents or legal guardians were perceived to be unreliable or unavailable for evaluation or study visits during the study period;
- •with any serious chronic disease (e.g., with signs of cardiac or renal failure or severe malnutrition), including progressive neurological disease and asthma;
- •with Down's syndrome or other known cytogenetic disorders;
- •with a known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids;
- •who received any blood products, including immunoglobulin, in the period from six months prior to vaccination through to the conclusion of the study;
- •for whom there was intent to administer any other investigational vaccine or agent from one month prior to enrollment through to the conclusion of the study;
- •with an immunosuppressed or compromised individual in the same playroom or living in the same household;
- •who, at any time prior to entry into this study, received a dose of any influenza vaccine (commercial or investigational);
- •with a documented history of hypersensitivity to egg or egg protein;
- •with a respiratory illness with wheezing within two weeks prior to enrollment;
- •who received aspirin (acetylsalicylic acid) or aspirin-containing products in the two weeks prior to enrollment or for whom use was anticipated during the study;
- •who were administered any live virus vaccine within one month prior to enrollment or expected receipt of another live virus vaccine within one month of vaccination in this study;
- •who were administered any inactivated vaccine within two weeks prior to enrollment or expected receipt of another inactivated vaccine within three weeks of vaccination in this study;
- •with any medical conditions that in the opinion of the investigator might interfere with interpretation of the study results.
结局指标
主要结局
The primary endpoint of the study was the determination of the proportion of placebo recipients from whom any of the vaccine strains were isolated.
次要结局
- The endpoint for children who received CAIV-T was the first nasal swab scored positive for viral shedding in
- which the vaccine virus phenotype (cold-adapted and temperature sensitive) or genotype (6:2 reassortant) was
- not preserved. Genotypic and phenotypic stability were summarized as the proportion of all vaccine viruspositive
- isolates which retained the cold-adapted phenotype, temperature-sensitive phenotype or the 6:2
- reassortant genotype of the vaccine strains.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)Safety IssuesNCT03109600PT Bio Farma100
已完成
3 期
A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related ComplicationsInfluenzaNCT01998477Novartis Vaccines430
已完成
1 期
A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected InfantsPneumococcal InfectionsHIV InfectionsNCT00000829National Institute of Allergy and Infectious Diseases (NIAID)60
已完成
2 期
A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza VaccineInfluenza, HumanNCT04669691Seqirus420
已完成
2 期
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)Hodgkin's LymphomaNon-Hodgkin's LymphomaChronic Myelogenous LeukemiaAcute Myelogenous LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromeNCT00285259Astellas Pharma Inc112